"Xenon Pharmaceuticals Inc. announced the results of its June 2, 2026, annual meeting, where shareholders approved the 2026 Equity Incentive Plan and elected eight directors. Approximately 93.54% of the company's common shares were represented at the meeting, which also included the approval of executive compensation and the appointment of PricewaterhouseCoopers LLP as auditor."
